Work

A phase I study of TR64, a VEGFR/CSF1R/c-KIT small molecule inhibitor, for the treatment of advanced malignant solid tumors.

Year: 2025

Type: article

Study design: Clinical Trial

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.e15146

Authors: Hongtao Li, Funan Liu, Jun Qian, Yang Shu, Aoli Wang, Li Wang

Institutions: First Affiliated Hospital of Bengbu Medical College, First Hospital of China Medical University

Language: English

Topic: Angiogenesis and VEGF in Cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410815648

FWCI:

Cites:

Cited by:

Related to: 10